Di Minno A, et al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood. Rev. (2017) 31(4):193-203.
 Ruff CT, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (2014)383(9921):955-62.
 Stacy Z. Novel oral anticoagulants for venous thromboembolism prophylaxis after total hip or knee replacement: an update on rivaroxaban (Xarelto). Pharm. Ther. (2013)38(1):45.
 Fox KA, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Europ. Heart. J. (2011)32(19):2387-94.
 Investigators EP. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New. Engl. J. Med. (2012)366(14):1287-97.
 Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor Xa inhibitor. Curr. Clin. Pharm. (2014)9(1):75-83.
 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin. Pharmacokinetics. (2014)53(1):1-16.
 Kubitza D, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Brit. J. Clin. Pharmacol. (2010)70(5):703-12.
 Mueck W, Kubitza D, Becka M. Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Brit. J. Clin. Pharmacol. (2013)76(3):455-66.
 Sherid M, et al. Risk of gastrointestinal bleeding with rivaroxaban: a comparative study with warfarin. Gastroenterol. Res. Pract. (2016) 2016: 9589036.
 Raschi E, et al. Liver injury with novel oral anticoagulants: assessing post‐marketing reports in the US Food and Drug Administration adverse event reporting system. Brit. J. Clin. Pharmacol. (2015)80(2):285-93.
 Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG. Reversing factor Xa inhibitors–clinical utility of andexanet alfa. J. Blood. Med .(2017) 8:141.
 Trujillo T, Dobesh PP. Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs (2014)74(14):1587-603.
 Mayet AY, Alsaqer AI, Alhammad AM, Al-Omar HA. Rivaroxaban prescribing in a Saudi tertiary care teaching hospital. Saudi Pharmaceutical Journal (2018)26(6):775-9.
 Whitworth MM, Haase KK, Fike DS, Bharadwaj RM, Young RB, MacLaughlin EJ. Utilization and prescribing patterns of direct oral anticoagulants. Int. J. Gen. Med. (2017)10:87.
 Tellor K, Patel S, Armbruster A, Daly M. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. J. Clin. Pharm. Ther. (2015) 40(4):447-51.
 Isaacs AN, Doolin M, Morse C, Shiltz E, Nisly SA. Medication utilization evaluation of dabigatran and rivaroxaban within a large, multi-center health system. Am. J. Health. Syst. Pharm. (2016)73(5):S35-S41.
 Chowdhry U, Jacques A, Karovitch A, Giguère P, Nguyen ML. Appropriateness of dabigatran and rivaroxaban prescribing for hospital inpatients. Can. J. Hosp. Pharm.
 Ashrafi F, Rezaie N, Mousavi S. New indications for dabigatran: A suggestion from a drug use evaluation study. J. Res. Pharm. Pract. (2017)6(4):211.